Technical Analysis for BMEA - Biomea Fusion, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -1.78% | |
| Narrow Range Bar | Range Contraction | -1.78% | |
| Wide Bands | Range Expansion | -1.78% | |
| NR7 | Range Contraction | -2.43% | |
| Narrow Range Bar | Range Contraction | -2.43% |
| Alert | Time |
|---|---|
| Outside Day | about 5 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
| Down 2 % | about 5 hours ago |
| 60 Minute Opening Range Breakdown | about 5 hours ago |
| Down 1% | about 6 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
T
TraderMike about 1 year ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 23.92 |
| 52 Week Low | 3.61 |
| Average Volume | 1,489,266 |
| 200-Day Moving Average | 12.93 |
| 50-Day Moving Average | 9.32 |
| 20-Day Moving Average | 6.15 |
| 10-Day Moving Average | 4.91 |
| Average True Range | 0.80 |
| RSI (14) | 31.03 |
| ADX | 31.97 |
| +DI | 18.58 |
| -DI | 40.05 |
| Chandelier Exit (Long, 3 ATRs) | 9.54 |
| Chandelier Exit (Short, 3 ATRs) | 6.01 |
| Upper Bollinger Bands | 11.34 |
| Lower Bollinger Band | 0.96 |
| Percent B (%b) | 0.33 |
| BandWidth | 168.79 |
| MACD Line | -1.56 |
| MACD Signal Line | -1.62 |
| MACD Histogram | 0.055 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.95 | ||||
| Resistance 3 (R3) | 5.00 | 4.87 | 4.86 | ||
| Resistance 2 (R2) | 4.87 | 4.73 | 4.85 | 4.83 | |
| Resistance 1 (R1) | 4.65 | 4.65 | 4.58 | 4.60 | 4.80 |
| Pivot Point | 4.52 | 4.52 | 4.48 | 4.49 | 4.52 |
| Support 1 (S1) | 4.29 | 4.38 | 4.23 | 4.24 | 4.04 |
| Support 2 (S2) | 4.16 | 4.30 | 4.14 | 4.01 | |
| Support 3 (S3) | 3.94 | 4.16 | 3.98 | ||
| Support 4 (S4) | 3.89 |
